Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability Study of SHR2554 Tablets in Healthy Adults
NCT05049083Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Dec 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zeprumetostat in lymphoma (2 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last measurable concentration and 5 more. Status: unknown.
02
Drugs
zeprumetostat
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT05049083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05049083.